Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 7/20 | 0.49 |
| ▸ | THRB | P10828 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.46 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5483053 | 0.81 | PTGDR2 (0.56) | PTGDR2TP53THRBLMNAMAPT | |
| SCHEMBL5471805 | 0.81 | PTGDR2 (0.58) | PTGDR2TP53THRBMAPTKMT2A | |
| SCHEMBL5479106 | 0.75 | PTGDR2 (0.68) | PTGDR2THRBMAPTKMT2AHPGD | |
| SCHEMBL5476953 | 0.75 | KDM4E (0.83) | PTGDR2MAPTHPGDKDM4EALDH1A1 | |
| SCHEMBL5480255 | 0.72 | PTGDR2 (0.70) | PTGDR2THRBMAPTKDM4EALDH1A1 | |
| SCHEMBL4036640 | 0.72 | ALDH1A1 (0.55) | PTGDR2TP53LMNAMAPTKMT2A | |
| SCHEMBL5479153 | 0.72 | PTGDR2 (1.00) | PTGDR2HPGDKDM4EALDH1A1 | |
| SCHEMBL5479109 | 0.70 | PTGDR2 (0.64) | PTGDR2THRBMAPTKMT2AHPGD | |
| SCHEMBL5487635 | 0.69 | HTT (0.45) | TP53LMNAMAPTKMT2AMEN1 | |
| SCHEMBL5472266 | 0.69 | PTGDR2 (0.80) | PTGDR2TP53LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060040976-A1 | Thiobenzimidazole derivatives | TEIJIN LIMITED | 2006-02-23 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| EP-1097926-A1 | THIOBENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | PTGDR2 2748/4885TP53 2364/4885THRB 2154/4885 |
| US-20060040976-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | PTGDR2 2748/4885TP53 2364/4885THRB 2154/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | PTGDR2 3468/4885TP53 2334/4885THRB 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.